Podcast Index
Browse podcasts by category, open recent episodes, and download audio to listen offline.
Hematologic Oncology Update
Dr. Neil Love
Nursing & Healthcare Exam Prep
Ran Chen, EA, CFP®
The Forties Formula
Amanda Lim & Jasmin Dhillon
Dr. John Campbell
Campbellteaching
TED-Ed
TED-Ed
Experiencer Interviews
Mr. Grey
Finance Exam Prep
Ran Chen, EA, CFP®
The Poison Lab
Clinical Toxicology LLC
Fluent Fiction - Norwegian
FluentFiction.org
Fluent Fiction - Polish
FluentFiction.org
Fluent Fiction - Dutch
FluentFiction.org
Fluent Fiction - Korean
FluentFiction.org
Fluent Fiction - German
FluentFiction.org
Fluent Fiction - French
FluentFiction.org
Fluent Fiction - Italian
FluentFiction.org
Fluent Fiction - Mandarin Chinese
FluentFiction.org
Fluent Fiction - Japanese
FluentFiction.org
Fluent Fiction - Hungarian
FluentFiction.org
Fluent Fiction - Danish
FluentFiction.org
Fluent Fiction - Swedish
FluentFiction.org
Fluent Fiction - Vietnamese
FluentFiction.org
Fluent Fiction - Greek
FluentFiction.org
Fluent Fiction - Serbian
FluentFiction.org
Fluent Fiction - Hindi
FluentFiction.org
Fluent Fiction - Ukrainian
FluentFiction.org
FluentFiction - Afrikaans
FluentFiction.org
FluentFiction - Romanian
FluentFiction.org
FluentFiction - Croatian
FluentFiction.org
FluentFiction - Czech
FluentFiction.org
FluentFiction - Finnish
FluentFiction.org
FluentFiction - Bulgarian
FluentFiction.org
FluentFiction - Latvian
FluentFiction.org
FluentFiction - Indonesian
FluentFiction.org
FluentFiction - Estonian
FluentFiction.org
FluentFiction - Slovak
FluentFiction.org
FluentFiction - Slovenian
FluentFiction.org
FluentFiction - Irish
FluentFiction.org
Education
Dr. Neil Love
Featuring perspectives from Dr Courtney D DiNardo and Dr Harry Paul Erba, including the following topics:Introduction (0:00)Current Management Approaches for FLT3- and IDH-Mutated Acute Myeloid Leukemia (AML) — Dr DiNard...
Featuring perspectives from Dr Anthony M Hunter and Dr Abdulraheem Yacoub, including the following topics:Introduction (0:00)Systemic Mastocytosis — Dr Hunter (9:33)Myelofibrosis — Dr Yacoub (29:40)CME information and se...
Featuring perspectives from Dr Hans Lee and Dr Noopur Raje, including the following topics:Introduction (0:00)Integrating Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies into the Management of Relapsed...
Featuring perspectives from Dr John N Allan and Dr Adam Kittai, including the following topics:Introduction (0:00)Current Management of Newly Diagnosed Chronic Lymphocytic Leukemia — Dr Allan (8:47)Noncovalent Bruton Tyr...
Featuring perspectives from Dr Manali Kamdar, Dr Krish Patel and Dr Gilles Salles, including the following topics:Introduction (0:00)Antibody-Drug Conjugates and Other Novel Strategies for the Management of Diffuse Large...
Dr Jennifer R Brown and Prof Wojciech Jurczak discuss the selection and sequencing of Bruton tyrosine kinase-targeted therapy for patients with chronic lymphocytic leukemia and summarize major advances in the treatment l...
Dr Amir Fathi from Massachusetts General Hospital in Boston, Massachusetts, and Dr Eunice S Wang from Roswell Park Comprehensive Cancer Center in Buffalo, New York, discuss key clinical trial data surrounding the use of ...
Dr Paul G Richardson from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses how CELMoDs function, available data with these agents and their possible future role in the treatment of multiple myeloma.CM...
Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatm...
Dr Paul G Richardson from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses how CELMoDs function, available data with these agents and their possible future role in the treatment of multiple myeloma.CM...
Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatm...
Dr Bijal Shah from Moffitt Cancer Center in Tampa, Florida, discusses the role of BiTEs in the management of ALL.CME information and select publications here.
Prof Constantine Tam from Monash University in Melbourne, Australia, reviews recent datasets and discusses their implications for current and future management of chronic lymphocytic leukemia.CME information and select p...
Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatm...
Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatm...
Dr Natalie S Callander from the University of Wisconsin Carbone Cancer Center in Madison and Dr Paul G Richardson from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss the potential role of CELMoDs in the m...
Dr Sagar Lonial from Winship Cancer Institute in Atlanta, Georgia, discusses recent clinical developments with BCMA-targeted therapy and investigational agents for relapsed/refractory multiple myeloma presented at ASH 20...
Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston, Dr Cindy Neunert from Columbia University Irving Medical Center in New York and Prof Francesco Zaja from ASUGI in Trieste, Italy discuss cases of immune ...
Dr Sagar Lonial from Winship Cancer Institute in Atlanta, Georgia, discusses recent clinical developments with BCMA-targeted therapy and investigational agents for relapsed/refractory multiple myeloma presented at ASH 20...
Prof Michael Dickinson from Peter MacCallum Cancer Centre in Melbourne, Australia, and Dr Laurie H Sehn from the University of British Columbia in Vancouver, Canada, discuss clinical cases and recent findings from the 20...
Fill in the form below. Make sure to select both Country and Genres.
Send us a message below. We will get back to you within 24 hours.